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Introduction {#sec1}
============

Meningitis, encephalitis, and meningoencephalitis are caused by various pathogens, but viral aetiologies are the most common cause [@bib1], [@bib2], [@bib3], [@bib4]. Among these, enterovirus (EV), herpes simplex type 1 and 2 (HSV-1 and HSV-2), and varicella zoster virus (VZV) are the most frequent viruses associated with encephalitis, meningoencephalitis, and meningitis in paediatric and adult populations [@bib1], [@bib2], [@bib4], [@bib5], [@bib6], [@bib7]. The prevalence of other viruses varies according to the geographical location and immune status of the patient.

During the last two decades, the implementation of molecular assays as a complement to serological assays, immunohistochemistry, and culture have improved the diagnosis of viral central nervous system (CNS) infections. Nevertheless, these assays have limitations because of their targeted approach. Apart from technical limitations, the diagnosis of viral CNS infections is subject to several issues, such as the type of sample (cerebrospinal fluid (CSF) or brain biopsy), the timeline of sample collection, and the different pathogenic mechanisms of viruses. Despite technical progress, approximately one-half of encephalitis, meningoencephalitis, and meningitis cases remain of unknown origin [@bib1], [@bib2], [@bib5], [@bib7].

High-throughput sequencing (HTS) has brought new perspectives to CNS infection investigations. Although HTS has been recently integrated in encephalitis management guidelines [@bib8], its use is still limited to specific clinical situations or research. The contribution of HTS warrants a better appraisal for further implementation in CNS infection management. This narrative review aims to evaluate the contribution and pitfalls of HTS for the aetiologic identification of viral encephalitis, meningoencephalitis, and encephalitis in paediatric and adult patients.

Methods {#sec2}
=======

A comprehensive PubMed search was conducted from 1 January 2008 to 2 August 2018 to identify human studies using the following MeSH and keywords research algorithm: '((central nervous system infection OR cerebrospinal fluid OR central nervous system) AND sequencing) AND virus'. Additional publications were identified from a review of full-text sources. The title and abstract of each citation were screened by two reviewers and assessed for eligibility by detailed analysis. Inclusion criteria were studies including patients with encephalitis, meningoencephalitis, or meningitis of unknown origin and reporting the use of HTS for the aetiologic identification of a viral origin in CNS samples. Exclusion criteria were reviews, animal studies, other CNS diseases, and studies addressing only technical aspects.

Results {#sec3}
=======

A total of 366 references were retrieved ([Fig. 1](#fig1){ref-type="fig"} ). Screening led to the exclusion of 324 references. Among the 42 studies retained, 13 were excluded in which HTS was performed as a sequencing technique [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21]. In these studies, HTS was performed as a sequencing technique after virus identification with (RT)-PCR assays (HSV-1, echovirus 18, Ebola virus, Toscana virus, EV D68 and 71, bornavirus, dengue virus serotype 3), focusing on their phylogenic classification and the comprehension of their epidemiology [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21]. Twenty-nine studies were selected for qualitative analysis (19 case reports, ten case series) ([Table 1](#tbl1){ref-type="table"} ).Fig. 1Flowchart of study selection. HTS, high-throughput sequencing; CNS, central nervous system.Fig. 1Table 1Characteristics of studies included in the narrative reviewTable 1ReferenceTiming of HTS useCharacteristics of patients with CNS samples screened with HTSHTSConfirmatory assaysGeographical originNumber of patientsImmunocompromised patientsPaediatric or adult patientsAgeDiagnosisClinical sample analysedProbable viral cause of CNS disease (number of patients)PlatformNucleic acid extraction methodsReport of control useNaccache SN *et al. Clin Infect Dis.* 2015 [@bib33]ProspectiveEurope1YesAdult42 yoEncephalitisCSF and brain tissueNovel HAstV-VA1 (1)HiSeq 2500RNA/DNAPositive controlRT-PCR, *in situ* hybridizationFrémond M-L *et al. J Pediatric Infect Dis Soc.* 2015 [@bib23]ProspectiveEurope1YesPaediatric14 yoEncephalitisBrain tissueNovel HAstV-VA1 (1)Ion ProtonRNANoRT-PCRSalzberg SL *et al. Neurol Neuroimmunol Neuroinflamm.* 2016 [@bib39]ProspectiveNorth America2Yes (1),No (1)Adult44 yo, 67 yoEncephalitisBrain tissueEBV (1)MiSeqDNANo*in situ* hybridizationWilson MR *et al. Ann Neurol.* 2017 [@bib30]ProspectiveOceania1YesAdult34 yoChronic meningoencephalitisCSF and brain tissueCache Valley virus (1)HiSeq 4000RNANegative controlRT-PCR, viral culture, immunohistochemistryWilson MR *et al. Am J Transplant.* 2017 [@bib40]ProspectiveNorth America1YesPaediatric14 yoMeningoencephalitisCSFWNV (1)HiSeq 2500RNANegative controlSerologyMorfopoulou S *et al. Acta Neuropathol.* 2017 [@bib41]ProspectiveEurope1YesPaediatric1.5 yoChronic encephalitisBrain tissueMumps virus (vaccine strain) (1)NextSeq 500RNANoRT-PCR, immunohistochemistry, serologyChiu CY *et al. Emerg Infect Dis. 2017*[@bib42]ProspectiveNorth America1YesAdult68 yoEncephalitisCSFSt Louis encephalitis virus (1)Not specifiedRNA/DNANoRT-PCR, serology, viral culturePalacios G. *et al. N Engl J Med.* 2008 [@bib26]RetrospectiveOceania2YesAdult63 yo and 64 yoEncephalitisCSF and brain tissueLCMV-related virus (2)GSL FLXRNANoRT-PCR, serologyQuan PL *et al. Emerg Infect Dis.* 2010 [@bib47]RetrospectiveNorth America1YesPaediatric15 yoEncephalitisBrain tissueHuman astrovirus undetermined (1)GSL FLXRNANoRT-PCR, immunohistochemistry immunofluorescenceBrown JR *et al. Clin Infect Dis.* 2015 [@bib31]RetrospectiveEurope1YesPaediatric1.5 yoEncephalitisBrain tissueNovel HAstV-VA1 (1)MiSeqRNAPositive controlRT-PCR, immunohistochemistryMorfopoulou S *et al.* N Engl J Med. 2016 [@bib25]RetrospectiveEurope1YesPaediatric11 moEncephalitisBrain tissueHuman coronavirus OC43 (1)HiSeq 2500RNANoRT-PCR, immunohistochemistrySato M *et al. J Clin Virol.* 2016 [@bib24]RetrospectiveAsia1YesPaediatric4 yoEncephalitisCSFNovel HAstV-MLB1 (1)MiSeqRNA/DNANoRT-PCRLum SH *et al. Transpl Infect Dis.* 2016 [@bib43]RetrospectiveEurope1YesPaediatric4 moEncephalitisBrain tissueNovel HAstV-VA1 (1)HiSeq 2500RNANoRT-PCRLipowski D *et al. J Infect Dis.* 2017 [@bib29]RetrospectiveEurope3YesAdultMedian 48 yo (range 27--54 yo)EncephalitisCSF and brain tissueTBEV (3)HiSeq 1500RNANoRT-PCRCordey S *et al. Emerg Infect Dis.* 2016 [@bib22]RetrospectiveEurope1NoAdult21 yoMeningitisCSFNovel HAstV-MLB2 (1)HiSeq 2500RNA/DNANoRT-PCRBenjamin LA *et al Emerg Infect Dis.* 2011 [@bib46]RetrospectiveAsia12NoPaediatric2 yo, 3 yo\
Other paediatric patients \<16 yoEncephalitisCSFParvovirus 4 (2)GS FLX TitaniumRNA/DNANoPCR, serologyPerlejewski K *et al. J Virol Methods* 2015 [@bib35]RetrospectiveEurope1NoAdult60 yoEncephalitisCSFHSV1 (1)MiSeqRNANegative and positive controlsPCRGuan H *et al. J Neurovirol.* 2016 [@bib36]RetrospectiveAsia4NoAdultMedian 43.5 yo (range 31--64 yo)MeningoencephalitisCSFHSV-1 (2), HSV-2 (1), VZV (1)BGISEQ-100DNANoPCRKawada J *et al. Sci Rep.* 2016 [@bib48]RetrospectiveAsia18NoPaediatricMedian 3 yo (range 3 mo to 15 yo)EncephalitisCSFMumps virus (1), coxsackie A9 virus (2)MiSeqRNA/DNAPositive controlRT-PCRArden KE *et al. J Med Virol*. 2017 [@bib49]RetrospectiveOceania1NoAdult51 yoEncephalitisCSFToscana virus (1)HiSeq 2500RNANoNoneTan le V *et al.* MBio. 2013 [@bib28]RetrospectiveAsia125NAPaediatric and adultNAEncephalitisCSFCyCV-VN (2)FLX genome sequencerRNA/DNANoPCRPhan TG *et al.* Virology. 2015 [@bib27]RetrospectiveAsia62NAPaediatric and adultPaediatric patients: 2 mo to 12 yo\
Adult patients: 15 to 72 yoEncephalitisCSFGemycirculavirus (3), CyCV-VN (1)MiSeqDNANoPCRChan BK *et al. PLoS One.* 2014 [@bib34]RetrospectiveNorth America7NANANAEncephalitisBrain tissueHSV-1 (3), MeV (2)HiSeq 2000RNANegative and positive controlsPCR, RT-PCRPhan TG *et al. Arch Virol.* 2016 [@bib37]RetrospectiveNorth America53NAPaediatric6 yo\
Other patients: NAEncephalitisCSFHuCSFDV1 (1)MiSeqRNA/DNANoPCRGreninger AL *et al. Genome Med.* 2015 [@bib32]ProspectiveNorth America1NoPaediatric15 yoEncephalitisCSF and brain tissueNoneMiSeqRNANegative control--Wilson MR *et al. Ann Neurol.* 2015 [@bib45]ProspectiveNorth America1YesAdult74 yoEncephalitisCSFNoneHiSeq 2500RNANegative control--Wilson MR *et al. N Engl J Med.* 2014 [@bib44]ProspectiveNorth America1YesPaediatric14 yoMeningoencephalitisCSFNoneMiSeqDNANegative control--Christopeit M *et al. Ann Hematol.* 2016 [@bib38]ProspectiveEurope1YesAdult65 yoEncephalitisCSFNoneNot specifiedRNANegative and positive controls--Mongkolrattanothai K *et al. J Pediatric Infect Dis Soc.* 2017 [@bib50]RetrospectiveNorth America1NoPaediatric11 yoEncephalitisCSFNoneHiSeqRNA/DNANegative and positive controls--[^1]

Characteristics of patients with CNS samples screened with HTS {#sec3.1}
--------------------------------------------------------------

Fourteen and 13 studies concerned paediatric and adult cases, respectively, and two studies concerned both populations ([Table 1](#tbl1){ref-type="table"}). HTS was performed in 307 cases (52 adults; 123 paediatric (\<18 years); 132 cases with no information on age). Twenty-five studies reported patient age (median age, 14 years; range, 3 months to 68 years). Diagnostic criteria for encephalitis, meningoencephalitis, and meningitis were inconsistently reported. Immune status was reported for 60 patients and comprised 20 immunocompromised (nine paediatric, 11 adults) and 40 immunocompetent patients (22 paediatric, eight adults). Studies came from a wide range of regions: Europe (ten), North America (ten), Asia (six), and Oceania (three) ([Table 1](#tbl1){ref-type="table"}).

Clinical samples analysed with HTS {#sec3.2}
----------------------------------

When brain specimens were available, pathological examination provided proof of diagnosis of encephalitis. CSF analysis results were reported in 25 patients of 20 studies, with the white blood cell count ranging from 1 to 494 cell/mm^3^ in encephalitis and meningoencephalitis cases and 915 cell/mm^3^ in the only meningitis case [@bib22]; three publications reported normal CSF analysis without any description [@bib23], [@bib24], [@bib25]. HTS was performed on individual CSF and brain specimens in 129 and 21 patients, respectively. CSF samples of 162 patients were pooled for HTS analysis [@bib26], [@bib27], [@bib28]. HTS was performed on CSF and brain specimens in five patients [@bib26], [@bib29], [@bib30], [@bib31], [@bib32]. Positive results on both samples were obtained in a Cache Valley virus chronic meningoencephalitis case [@bib30] and positive results on brain biopsies only were reported in two human astrovirus (HAstV)-VA1 and tick-borne encephalitis (TBEV) cases [@bib29], [@bib33]. In one patient, HTS analysis did not identify a viral cause, but *Balamuthia mandrillaris* was identified in both CSF and brain biopsy [@bib32]. Despite limitations because of publication bias, the overall diagnostic yield for a viral aetiology according to sample type was estimated to be higher for brain specimens (16/21 (76.2%) positive samples) than for CSF samples (26/291 (8.9%) positive samples).

HTS use in microbiological investigations {#sec3.3}
-----------------------------------------

Detailed microbiological investigations performed prior to HTS varied according to local practice and were not reported in seven studies [@bib24], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39]. In most studies, viruses identified with HTS were not part of the microbiological work-up, except in three cases where HTS identified a virus for which diagnostic assays were negative during routine investigation. These included a West Nile virus (WNV) identified in the CSF sample of a renal transplant recipient with meningoencephalitis and a negative serological assay [@bib40]. HSV-1 was identified in an encephalitis case [@bib35]. A vaccine strain of mumps virus was identified in a brain specimen of an immunosuppressed child with chronic encephalitis in whom (RT)-PCR for mumps on a CSF sample was negative as the assay did not target vaccine strains [@bib41].

HTS was performed retrospectively in 18 studies and prospectively as part of the initial work-up in 11 case reports with an impact on the clinical management of three immunocompromised patients: a child with encephalitis associated with HAstV-VA1 [@bib23]; an adult with encephalitis associated with HAstV-VA1 [@bib33]; and an adult with chronic meningoencephalitis associated with Cache Valley virus [@bib30]. Turnaround times were reported in ten studies [@bib23], [@bib31], [@bib33], [@bib36], [@bib39], [@bib40], [@bib42], [@bib43], [@bib44], [@bib45]. Among publications in which HTS was used prospectively, turnaround times ranged from 48 hours to 7 days [@bib23], [@bib33], [@bib39], [@bib40], [@bib42], [@bib44], [@bib45].

Virus identification with HTS {#sec3.4}
-----------------------------

HTS performed on pooled or individual samples and/or subsequent confirmatory assays allowed the identification of a potential causal virus in 41 of 307 patients (13.4%), comprising 15 paediatric cases (eight immunocompromised cases), 17 adult cases (nine immunocompromised cases) and nine cases for whom age was not specified; median age was 21 years (range 3 months to 68 years). [Fig. 2](#fig2){ref-type="fig"} shows the distribution of viruses identified according to patient immune status and clinical manifestations. HTS allowed the identification of viruses previously unknown or unexpected as a cause of CNS infection (*n* = 10) and thus not screened during diagnostic investigations ([Table 1](#tbl1){ref-type="table"}). These included parvovirus 4 (two) [@bib46], human coronavirus OC43 (one) [@bib25], and novel HAstV-MLB2 (one) [@bib22] identified in immunocompetent patients. A mumps virus vaccine strain (one) [@bib41], HAstV (undetermined specie; one) [@bib47], HAstV-VA1 (four) [@bib23], [@bib31], [@bib33], [@bib43], and HAstV-MLB1 (one) [@bib24] were identified in immunocompromised patients. A gemycircularvirus was also identified, but its causal role in encephalitis is under debate [@bib27]. Three novel viral species or strains were identified in CSF samples of patients with encephalitis ([Table 1](#tbl1){ref-type="table"}): human CSF-associated densovirus 1 (HuCSFDV1) [@bib37]; cyclovirus Viet-Nam (CyCV-VN) [@bib28]; and lymphocytic choriomeningitis virus (LCMV)-related arenavirus [@bib26]. HTS analysis also identified viruses known to be responsible for CNS infections (*n* = 11) and not screened or detected by routine assays (HSV-1, HSV-2, VZV, Epstein--Barr virus (EBV), TBEV, WNV, Cache Valley, Saint Louis encephalitis, Toscana, mumps, measles, and coxsackie A9 virus) [@bib29], [@bib30], [@bib34], [@bib35], [@bib39], [@bib40], [@bib42], [@bib48], [@bib49] ([Table 1](#tbl1){ref-type="table"}).Fig. 2Distribution of viruses identified with high-throughput sequencing and/or subsequent confirmatory assays in the cerebrospinal fluid and brain samples of 41 patients with a potential viral cause of central nervous system infection, according to immune status and clinical manifestations. The number of patients in whom each virus has been identified is mentioned in brackets. Enc., encephalitis; MeEnc., meningoencephalitis; Me., meningitis; CyCV-VN, cyclovirus Viet-Nam; HSV, herpes simplex virus; MeV, measles virus; HuCSFDV1, human CSF-associated densovirus 1; CV-A9, coxsackie virus A9; TosV, Toscana virus; VZV, varicella zoster virus; HAstV, human astrovirus; TBEV, tick-borne encephalitis virus; LCMV, lymphocytic choriomeningitis virus; EBV, Epstein--Barr virus; SLEV, Saint Louis encephalitis virus; CoV, coronavirus; WNV, West Nile virus; undet., undetermined.Fig. 2

HTS protocols and controls {#sec3.5}
--------------------------

Most studies performed nucleic acid extraction protocols dedicated to RNA, or RNA and DNA. Thirteen RNA and seven DNA viral species were identified ([Table 1](#tbl1){ref-type="table"}). One study reported the identification of HSV-1 in a CSF sample after RNA extraction protocol [@bib35]. Six studies where HTS analysis was not restricted to the detection of viruses resulted in the identification of bacterial (*Brucella melitensis* and *Leptospira santarosai*) [@bib44], [@bib50], mycobacterial (*Mycobacterium tuberculosis*) [@bib39], and parasitic (*Balamuthia mandrillaris*) [@bib32], [@bib45] or fungal (*Candida tropicalis* and *Fusarium solani* and *oxysporum*) [@bib38] pathogens.

The use of controls was not systematically reported. Nine studies reported various negative control samples, such as brain specimens without encephalitis [@bib34], CSF samples from patients without infection [@bib30], [@bib32], [@bib35], [@bib38], [@bib40], [@bib45], serum samples, and water or elution buffer [@bib30], [@bib44], [@bib45], [@bib50]. Viral sequences of negative controls were not consistently described. Positive controls, such as CSF or serum samples positive for DNA or RNA viruses, were rarely reported or used [@bib33], [@bib35], [@bib38], [@bib48], [@bib50].

To address the specificity of HTS results, other techniques were performed to confirm HTS results in all studies, except one [@bib49]. (RT)-PCR assays were performed in samples from 37 patients and were positive in at least one sample in 36 patients. HTS results were also confirmed with serological assays [@bib26], [@bib40], [@bib41], [@bib46], immunohistochemistry, and *in situ* hybridization [@bib25], [@bib30], [@bib31], [@bib33], [@bib39], [@bib41], [@bib47]. Viral culture confirmed the presence of a replicative Saint Louis encephalitis virus in a CSF sample [@bib42], but was unsuccessful concerning a Cache Valley virus [@bib30].

Discussion {#sec4}
==========

Contribution of HTS in identifying viral causes of encephalitis, meningoencephalitis and meningitis {#sec4.1}
---------------------------------------------------------------------------------------------------

HTS offers the possibility of investigating viral aetiologies of CNS infections by an unbiased approach when work-up according to guidelines fails to identify a causal pathogen. Based on the studies retrieved, its diagnostic yield for a viral aetiology is difficult to estimate, particularly because of publication bias (high number of case reports), methodological heterogeneity, and a lack of systematic prospective studies. When focusing specifically on case series, the diagnostic yield for the identification of a viral cause was approximately 10%, but this result should be interpreted with caution in the light of the evolution of the technique from 2008 to 2017. Among the studies reviewed, the HTS contribution is evident not only for the identification of a potential causal virus in CNS infections of unknown origin, but also in the detection of novel or divergent viruses [@bib26], [@bib28], [@bib37]. Similar to other techniques, the type of sample used for analysis is of particular importance. Despite diverse HTS protocols and publication bias, HTS seemed to have a higher diagnostic yield in brain specimens than in CSF samples. The diagnostic yield was particularly low in two studies where HTS was performed on CSF supernatant [@bib27], [@bib28]. HTS also shows its clinical value in situations where the viral pathogenic mechanisms and specific clinical situations impairs the results of conventional assays [@bib40]. Among immunocompetent patients, HTS led to the identification of viruses not previously associated with CNS infections (parvovirus 4, CyCV-VN, gemycircularvirus, and novel HAstV-MLB2) [@bib22], [@bib27], [@bib28], [@bib46].

HTS clinical impact was mainly demonstrated among immunocompromised patients, with most studies dedicated to this population. It was performed prospectively in 11 cases and led to a change in clinical management in three [@bib23], [@bib30], [@bib33]. The rapid decision to perform HTS, short HTS turnaround times, and the efficient interpretation of results were determinant for the management of these latter patients. Among immunocompromised patients, HTS contributed to the detection of viruses for which no assay was performed during conventional work-up: viruses known to cause CNS infections (TBEV, WNV, Cache Valley virus, Saint-Louis encephalitis virus, EBV) [@bib29], [@bib30], [@bib39], [@bib40], [@bib42], viruses not known to be responsible for CNS infections (novel HAstV-VA1, HAstV-MLB1, human coronavirus OC43, mumps virus vaccine strain) [@bib23], [@bib24], [@bib25], [@bib31], [@bib33], [@bib41], [@bib43], [@bib47], and novel viruses (LCMV-related arenavirus) [@bib26]. Focusing on novel HAstV, HTS brought new insights in our understanding of their association with CNS infections [@bib22], [@bib23], [@bib24], [@bib31], [@bib33], [@bib43]. Furthermore, all (RT)-PCR assays performed retrospectively confirmed HTS results, thus highlighting the specificity of HTS.

Issues of HTS in identifying viral causes of encephalitis, meningoencephalitis and meningitis {#sec4.2}
---------------------------------------------------------------------------------------------

In the absence of standardization, the methodological heterogeneity of studies is striking, not only concerning pre-analytic steps, but also HTS *per se*, with the use of diverse HTS platforms, single or paired protocols, as well as diverse bioinformatic pipelines and databases. The use of positive controls as quality controls was only reported in seven studies [@bib31], [@bib33], [@bib34], [@bib35], [@bib38], [@bib48], [@bib50]. Addressing the issue of contamination, only a few studies reported the use of negative controls [@bib30], [@bib32], [@bib34], [@bib35], [@bib38], [@bib40], [@bib44], [@bib45], [@bib50]. Viral sequences assigned to viruses not considered as the cause of CNS infection were not consistently performed: 12 studies provided a description for one CNS sample or more [@bib25], [@bib27], [@bib29], [@bib30], [@bib32], [@bib33], [@bib34], [@bib35], [@bib38], [@bib40], [@bib44], [@bib50]. For most of these viral sequences, no interpretation of results was explicitly provided. Among reads of viruses known to cause infections in humans, Anelloviridae [@bib51] and Herpesviridae were the most described in four and seven samples, respectively; human pegivirus reads were identified in one sample. The genome of the torque teno virus, a member of the Anelloviridae family, and human pegivirus have been identified in CNS samples, but without any association with a CNS disease so far [@bib52], [@bib53], [@bib54], [@bib55], [@bib56], [@bib57]. Other viral sequences were mostly assigned to viruses infecting plants or non-vertebrates and were considered to be reagent contaminants. The minimal description of these HTS 'background' results impairs the comprehension of the composition of the CNS virome. Furthermore, the integration of HTS results in the clinical context is of particular importance and the absence of standardization of any reporting methods precludes an objective interpretation of these results.

Finally, HTS-negative results could be interpreted in the context of several clinical and technical aspects that could impact on the sensitivity of the method. First, from a clinical point of view, differences in diagnostic yield from a biopsy compared with CSF samples could be explained by several factors: patient selection (cases of encephalitis); the type of sample (e.g. multiple pooled post-mortem brain samples); and the timeline of sampling in the context of encephalitis (biopsy positivity could possibly be less affected by time than CSF). From a technical point of view, it should be considered that this narrative review includes studies from 2008 to 2018 and thus takes into account the tremendous evolution of the HTS technique over this last decade. Several technical issues need to be considered for the interpretation of negative results: pre-analytic steps (e.g. the use of fresh, frozen, or paraffin-embedded samples for analysis, extraction protocols, fragmentation methods, library preparation, paired-end versus single-end protocols); sequencing depth; sequencing platforms ([Table 1](#tbl1){ref-type="table"}); and the analysis of HTS raw data (e.g. mapping software, viral databases, and pipeline precision).

Perspectives for HTS implementation in the management of encephalitis, meningoencephalitis and meningitis {#sec4.3}
---------------------------------------------------------------------------------------------------------

This review highlights that the use of HTS in investigations concerning a viral cause of encephalitis, meningoencephalitis, and meningitis could extend not only to immunocompromised, but also to immunocompetent patients. Considering the selection and publication bias of the literature reviewed here, the negative predictive value for the aetiologic identification of viral encephalitis, meningoencephalitis, and meningitis is difficult to quantify and further studies are needed. HTS needs to be integrated in clinical management as a second-line technique or in parallel to first-line investigations when a standard work-up according to guidelines [@bib8], [@bib58] and additional investigations considering local epidemiology and specific clinical situations fail to identify a causal agent. Brain biopsy should also be considered. Furthermore, HTS is of particular interest for the screening of a large panel of viruses, particularly to avoid a restricted screening of low-volume clinical samples, such as in paediatric patients. HTS brought new perspectives to the investigations of infectious diseases. Notably, its unbiased approach is of particular interest in samples that would not usually be tested in specific syndromes. Its use may not only be restricted to CNS samples, but also extended to other clinical samples. This is illustrated by the positive results of (RT)-PCR assays performed on blood or plasma samples collected at the time of neurological manifestations, which allowed the identification of the same virus detected by HTS in CNS samples (parvovirus 4, LCMV-related arenavirus, novel HAstV-VA1, novel HAstV-MLB2) [@bib22], [@bib26], [@bib31], [@bib46]. This could be of particular interest when a cerebral biopsy cannot be performed and a disseminated infection occurs or is suspected, particularly in immunocompromised patients.

An early decision to perform HTS, short HTS turnaround times, and an efficient interpretation of results are major issues for allowing HTS to contribute to clinical management. For prospective HTS use in clinical routine, this timeframe should be as short as possible for clinical decision-making. Among publications in which HTS was used prospectively, reported turnaround times ranged from 48 hours to 7 days [@bib23], [@bib33], [@bib39], [@bib40], [@bib42], [@bib44], [@bib45].

HTS use is still restricted to a limited number of diagnostic laboratories considering the cost of analysis and informatics infrastructures needed (e.g. costs of sequencing platforms, computing resources, data storage). Despite the expanding use of HTS in clinical microbiology, the surprisingly low number of studies retrieved for this review might be explained for several reasons, including financial limitations when considering the costs of the analysis, the need for shorter turnaround times, and the limitations cited above.

Addressing the question of the proof of causality, particularly in the context of pathogen discovery, Lipkin proposed several criteria for pathogen causality with grading certainty according to confirmation with serological assays or culture for instance [@bib59]. Most studies confirmed HTS results with (RT)-PCR assays and a few with cell culture, serological assays, and immunohistochemistry. Thus, HTS should be implemented in clinical routine in association with other diagnostic tests. In most studies, the approach to establish causality was not explicitly described, but was reported as the temporal association of clinical manifestations and the identification of viral sequences of a specific virus using HTS on CNS samples at the time of manifestations. This process was only described in few studies. Similar to other molecular tests such as (RT)-PCR, the detection of viral sequences or genome in a clinical sample should be interpreted with caution in the clinical context. In a near future, the process for the establishment of causality in HTS analysis should be more transparent and should comprise multidisciplinary sessions involving infectious disease specialists and bioinformatics experts, not only for results concerning viruses unexpected to cause CNS infections. Finally, for HTS implementation in clinical routine, the question of standardization has to be addressed concerning HTS protocols, data analysis algorithms, reference databases and quality controls, and further prospective studies are needed [@bib60].

Conclusion {#sec5}
==========

This review shows that HTS contributed to the identification of potential viral aetiologies of encephalitis, meningoencephalitis, and meningitis of unknown origin in approximately 13% of cases and is of particular interest in immunocompromised patients. This unbiased or semi-unbiased approach led to the identification of novel viruses, viruses known or not expected to cause CNS infections. Standardized strategies are needed for the further implementation of HTS in clinical management. In centres where available, the decision to perform HTS should be considered early in the management of encephalitis, meningoencephalitis, and meningitis in as a second-line technique or in parallel to recommended investigations.
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[^1]: HTS, high-throughput sequencing; CNS, central nervous system; CSF, cerebrospinal fluid; y, years old; m, months old; NA, not available. HAstV, human astrovirus; EBV, Epstein-Barr virus; WNV, West Nile virus; LCMV, lymphocytic choriomeningitis virus; TBEV, tick-borne encephalitis virus; CyCV-VN, cyclovirus Viet-Nam; HSV, herpes simplex virus; VZV, varicella zoster virus; MeV, measles virus; HuCSFDV1, CSF-associated densovirus 1.
